LOGIN  |  REGISTER
C4 Therapeutics
Assertio

LifeSpeak Announces Fourth Quarter and Fiscal 2023 Results

March 21, 2024 | Last Trade: C$0.38 0.00 0.00
  • Fiscal 2023 revenue of $52.4 million, an increase of 11% over Fiscal 2022
  • Adjusted EBITDA1 for Fiscal 2023 of $13.0 million, representing an Adjusted EBITDA Margin1 of 25%
  • Total Number of Clients2 of 956 as at December 31, 2023

TORONTO, March 21, 2024 /CNW/ - LifeSpeak Inc. ("LifeSpeak" or the "Company") (TSX: LSPK), the leading whole-person wellbeing solution for employers, health plans and other organizations, announced today its financial and operational results for the three and 12 months ended December 31, 2023. All references to dollar values in this press release are in Canadian dollars, unless otherwise indicated.

"Fiscal 2023 marks the third consecutive year of revenue growth for LifeSpeak," said Michael Held, CEO and Founder of LifeSpeak. "The addition of new customers, and greater revenue related to acquisitions drove this growth. Looking ahead, our pipeline of sales opportunities is diverse and growing. In addition,  as demonstrated by the participation of our senior management team and board members in our recent private placement, insider confidence in our business remains strong as we sharpen our focus on LifeSpeak's growth moving forward."  

Consolidated Business Highlights for the Three and 12 Months Ended December 31, 2023

(All capitalized terms not defined herein shall have the meaning ascribed to them in the Management's Discussion and Analysis for the three and 12 months ended December 31, 2023, unless otherwise stated)

  • Fourth quarter 2023 revenue reached $12.9 million, a decrease of 6% compared to the same period in 2022, largely due to one-time revenue recognized in the fourth quarter of 2022. Fourth quarter 2023 revenue was moderately higher than third quarter 2023 revenue.
  • ARR3 of $51.0 million as at December 31, 2023, representing a decrease of 3% over the same period in 2022. Of the $51.0 million of ARR3, approximately $43.4 million, or 85%, originated from enterprise clients, a 2% increase compared to the same period in 2022. Of the $51.0 million of ARR3, approximately 66% originated from clients outside of Canada.
  • As at December 31, 2023, no single client accounted for more than 5% of ARR3.
  • ARR3 is reported on a constant currency basis using a 1.30 USD:CAD exchange rate. When adjusting for the exchange rate at the end of the fourth quarter 2023 of 1.3226 USD:CAD, ARR3 would be approximately $51.6 million.
  • Fourth quarter 2023 Adjusted EBITDA1 of $2.7 million, a decrease of $2.1 million compared to the same period in 2022. The decrease is largely due to one-time revenue and cost adjustments recognized in the fourth quarter of 2022.
  • Fourth quarter 2023 Adjusted EBITDA1 Margin of 21%, a decrease when compared to an Adjusted EBITDA Margin1 of 35% in the comparable quarter of 2022, which is largely attributable to one-time revenue and cost adjustments recognized in the fourth quarter of 2022.
  • Adjusted EBITDA1 of $13.0 million for Fiscal 2023, an increase of $2.3 million when compared to Fiscal 2022.
  • Fourth quarter 2023 net loss of $17.7 million, a decrease from a net loss of $24.5 million in the fourth quarter of 2022. The decrease in net loss for the three months ended December 31, 2023, is primarily due to lower goodwill impairment.
  • Notable client additions for the fourth quarter of 2023 included Canada Goose, Virtusa Corporation and TravelBrands. Subsequent to quarter end, the Company added Accenture, Knitwell and Ascena Retail as new clients. 
  • Uptake in the expansion of multi-product clients continued with the close of new multi-product launches, including with Grant Thornton LLP in fourth quarter of 2023, and the successful closing of a cross-sale expansion with Amazon Canada subsequent to quarter end, among others.
  • The Company anticipates continued uptake in cross-sell as we further execute on opportunities within the current portfolio, as well as an increase in multi-product sales with net new clients.
  • Subsequent to quarter end, on March 14, 2024, the Company closed a private placement for gross proceeds of approximately $5.0 million. Proceeds of the private placement were used to repay outstanding senior indebtedness, resulting in total senior indebtedness of $66.4 million following repayment. The Company anticipates that amortization of the senior indebtedness will be approximately $1.8 million per quarter for 2024.
 

_____________________________

1

See "Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators" for a definition of "Adjusted EBITDA" and "Adjusted EBITDA Margin"

2

See "Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators" for a definition of "Number of Clients"

3

See "Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators" for a definition of "ARR"

  

ARR, Number of Clients, Consolidated Net Dollar Retention Rate and Logo Retention Rate

ARR3 was approximately $51.0 million as at December 31, 2023, with core enterprise client ARR3 of approximately $43.6 million.

ARR3 was broken down as follows over the last five quarters:

(In thousands of Canadian dollars)

Q4-
2022

Q1-
2023

Q2-
2023

Q3-
2023

Q4-
2023

Q4-2023

YoY Growth

Enterprise Client ARR

43,860

44,824

44,035

43,619

43,447

(1 %)

Embedded Solutions Clients & Other ARR

8,978

8,488

8,155

7,913

7,585

(16 %)

Total ARR

52,838

53,312

52,190

51,532

51,032

(3 %)

Total Number of Clients2 was 956 as at December 31, 2023, compared to 1,002 as at December 31, 2022.

Number of Clients2 was broken down as follows over the last five quarters:

  
 

Q4-

2022

Q1-

2023

Q2-

2023

Q3-
2023

Q4-
2023

Q4-2023

YoY Growth

Total Enterprise Clients

983

972

979

973

942

(4 %)

Total Embedded Solutions Clients

19

18

17

15

14

(26 %)

Total Number of Clients

1,002

990

996

988

956

(5 %)

Consolidated Net Dollar Retention Rate4 for the quarter was 87%, a 11% increase from the same period in 2022. Net Dollar Retention4 for Enterprise Clients was approximately 87% as at December 31, 2023, as compared to 94% for the comparative period in 2022. Enterprise Net Dollar Retention4 is lower primarily due to an increase in overall Enterprise Client churn, counteracted by cross-sell and multi-product opportunities within the existing Enterprise Client base.

Logo Retention Rate5 was 79% as at December 31, 2023 compared to 86% for the comparable period in 2022. The lower Logo Retention Rate5 is primarily attributable to the loss of smaller enterprise client logos within the portfolio of customers. Despite the decrease in Number of Clients4, the relative contribution to ARR3 of new clients is, on average, larger than that of lost clients.

See "Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators" for a definition, "Net Dollar Retention Rate".

5 See "Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators" for a definition, "Logo Retention Rate".

Financial Results for the Three and 12 Months Ended December 31, 2023:

Selected Consolidated Financial Information

Three Months Ended
December 31,

Fiscal Years Ended
December 31,

 

2023

2022

2023

2022

     

Revenue

12,949

13,755

52,407

47,370

Content development costs

1,285

1,158

5,086

4,771

 

11,664

12,597

47,321

42,599

     

Operating expenses:

    

Sales and marketing

2,747

3,641

10,870

13,327

General and administrative

6,655

6,131

26,031

26,439

Share-based compensation

532

1,413

4,138

8,844

Foreign exchange loss (gain)

1,657

(1,739)

1,924

(5,330)

Amortization and depreciation

3,976

3,715

16,033

14,992

 

15,567

13,161

58,996

58,272

     

Loss from operations

(3,903)

(564)

(11,675)

(15,673)

     

Acquisition and other costs (1)

-

-

-

7,589

Changes in fair value of on contingent consideration

-

(3,229)

(3,533)

(7,179)

Finance expense, net

3,188

2,089

10,398

8,764

Impairment

12,673

26,503

12,673

26,503

     

Loss before income taxes

(19,764)

(25,927)

(31,213)

(51,350)

Income taxes recovery

(2,089)

(1,383)

(4,952)

(3,434)

     

Net Loss

(17,675)

(24,544)

(26,261)

(47,916)

     

Loss per share - basic

(0.35)

(0.48)

(0.52)

(0.95)

Loss per share- diluted

(0.35)

(0.48)

(0.52)

(0.95)

     

Non-IFRS Measures and Non-IFRS Ratios

    

EBITDA (2)

(12,599)

(20,122)

(4,782)

(27,592)

Adjusted EBITDA (3)

2,717

4,816

12,985

10,690

Adjusted Net Income (Loss) (4)

(2,358)

395

(8,493)

(9,634)

Adjusted earnings (loss) per share – basic (5)

(0.05)

0.01

(0.17)

(0.19)

Adjusted earnings (loss) per share – diluted (6)

(0.05)

0.01

(0.17)

(0.19)

      

Notes:

 

(1)

Acquisition and other costs are comprised costs and expenses in connection with the Company's acquisitions and business integration costs.

(2)

"EBITDA" has the meaning ascribed herein under "Cautionary Note Regarding Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators".

(3)

"Adjusted EBITDA" has the meaning ascribed herein under "Cautionary Note Regarding Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators".

(4)

"Adjusted Net Income (Loss)" has the meaning ascribed herein under "Cautionary Note Regarding Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators".

(5)

"Adjusted earnings (loss) per share – basic" has the meaning ascribed herein under "Cautionary Note Regarding Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators".

(6)

"Adjusted earnings (loss) per share – diluted" has the meaning ascribed herein under "Cautionary Note Regarding Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators".

Conference Call Notification

The Company will subsequently hold a conference call to provide a business update on Thursday, March 21, 2024, at 8:00 a.m. ET hosted by:

  • Nolan Bederman, Executive Chairman
  • Michael Held, CEO
  • Michael McKenna, CFO

A question-and-answer session will follow the business update.

CONFERENCE CALL DETAILS

DATE:

Thursday, March 21, 2024

TIME:

8:00 a.m. ET

DIAL-IN NUMBERS:

1.833.950.0062 or 1.833.470.1428

REFERENCE NUMBER:

058906

This live call is also being webcast and can be accessed by going to:

https://events.q4inc.com/attendee/475714595

An archived telephone replay of the call will be available for two weeks by dialing 1.226.828.7578 or 1.866.813.9403 and entering access code 178125.   

Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators

LifeSpeak supplements its results of operations determined in accordance with IFRS with certain non-IFRS financial measures, non-IFRS ratios and key performance indicators that the Company believes are useful to investors, lenders and others in assessing its performance and which highlight trends its core business that may not otherwise be apparent when relying solely on IFRS measures. LifeSpeak management also uses non-IFRS measures, non-IFRS ratios and key performance indicators for purposes of comparison to prior periods, to prepare annual operating budgets, for the development of future projections and earnings growth prospects, to measure the profitability of ongoing operations and in analyzing our financial condition, business performance and trends. As such, these measures and indicators are provided as additional information to complement those IFRS measures by providing further understanding of the Company's results of operations from management's perspective, including how it evaluates its financial performance and how it manages its capital structure. LifeSpeak also believes that securities analysts, investors and other interested parties frequently use these non-IFRS measures, non-IFRS ratios and key performance indicators in the evaluation of issuers. These non-IFRS measures, non-IFRS ratios and key performance indicators are not recognized measures under IFRS and do not have a standardized meaning prescribed by IFRS and may include or exclude certain items as compared to similar IFRS measures, and such measures may not be comparable to similarly-titled measures reported by other companies. Accordingly, these measures and indicators should not be considered in isolation nor as a substitute for analysis of our financial information reported under IFRS.

Non-IFRS Measures, Non-IFRS Ratios and Reconciliation of Non-IFRS Measures

The Company uses non-IFRS measures, including "EBITDA", "Adjusted EBITDA", "Adjusted Net Income (Loss)", and the non-IFRS ratios, including "Adjusted earnings (loss) per share – basic", "Adjusted earnings (loss) per share – diluted" and "Adjusted EBITDA Margin". This press release also makes reference to "Annual Recurring Revenue" or "ARR", "Net Dollar Retention Rate", "Number of Clients" and "Logo Retention Rate", which are key performance indicators used in our industry.

EBITDA and Adjusted EBITDA 

"EBITDA" is defined as net income (loss) before income tax recovery, finance expenses, net and amortization and depreciation.

"Adjusted EBITDA" is defined as EBITDA before acquisition and other costs, share based compensation, foreign exchange loss (gain), impairment, changes in fair value of contingent consideration, synergies realized and additional one time items. These non-cash and/or non-recurring costs are independent events and incurred over several financial periods.

"Adjusted EBITDA Margin" is calculated as Adjusted EBITDA divided by revenue for the relevant period.

(In thousands of Canadian dollars)

Three Months Ended

December 31,

Fiscal Years Ended

December 31,

 

2023

2022

2023

2022

Net loss

(17,674)

(24,543)

(26,261)

(47,914)

Add:

    

Amortization and depreciation expense

3,976

3,715

16,033

14,992

Finance expense

3,188

2,089

10,398

8,764

Income tax recovery

(2,089)

(1,383)

(4,952)

(3,434)

EBITDA(1)

(12,599)

(20,122)

(4,782)

(27,592)

Add:

    

Acquisition and other costs (2)

-

-

-

7,589

Share-based compensation

532

1,413

4,138

8,844

Foreign exchange loss (gain)

1,657

(1,739)

1,924

(5,330)

Changes in fair value of contingent consideration

-

(3,229)

(3,533)

(7,179)

Impairment

12,673

26,503

12,673

26,503

Synergies realized (3)

33

501

631

2,912

Additional one-time costs (4)

421

1,489

1,934

4,943

Adjusted EBITDA (5)

2,717

4,816

12,985

10,690

Adjusted EBITDA Margin (6)

21 %

35 %

25 %

23 %

Notes:

 

(1)

"EBITDA" has the meaning ascribed herein under "Cautionary Note Regarding Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators".

(2)

Acquisition and other costs are comprised costs and expenses in connection with the Company's acquisitions and business integration costs.

(3)

Synergies realized relates to the impact of the full period of cost synergies related to the reduction of employees and professional services in relation to acquisitions.

(4)

One-time costs related to IPO specific adjustments, acquisitions specific adjustments and transition costs related to the Wellbeats acquisition.

(5)

"Adjusted EBITDA" has the meaning ascribed herein under "Cautionary Note Regarding Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators".

(6)

"Adjusted EBITDA Margin" has the meaning ascribed herein under "Cautionary Note Regarding Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators".

Adjusted Net Income (Loss) / Adjusted Earnings (Loss)

"Adjusted Net Income (Loss)" is defined as net income (loss) before acquisition and other costs, share based compensation, foreign exchange loss (gain), impairment, changes in fair value of contingent consideration, synergies realized and additional one-time items. These non-cash and/or non-recurring costs are independent events and incurred over several financial periods.

"Adjusted earnings (loss) per share – basic" is defined as Adjusted Net Income (Loss) divided by the weighted average number of shares outstanding – basic for the relevant period.

"Adjusted earnings (loss) per share – diluted" is defined as Adjusted Net Income (Loss) divided by the weighted average number of shares outstanding – diluted for the relevant period.

(In thousands of Canadian dollars)

Three Months Ended

December 31,

Fiscal Years Ended

December 31,

 

2023

2022

2023

2022

Net loss

(17,674)

(24,543)

(26,261)

(47,914)

Add:

    

Acquisition and other costs (1)

-

-

-

7,589

Share-based compensation

532

1,413

4,138

8,844

Foreign exchange loss (gain)

1,657

(1,739)

1,924

(5,330)

Changes in fair value of contingent consideration

-

(3,229)

(3,533)

(7,179)

Impairment

12,673

26,503

12,673

26,503

Synergies realized (2)

33

501

631

2,912

Additional one-time costs (3)

421

1,489

1,934

4,943

Adjusted Net Income (Loss) (4)

(2,358)

395

(8,494)

(9,632)

Adjusted earnings per share – basic (5)

(0.05)

0.01

(0.17)

(0.19)

Adjusted earnings per share – diluted (6)

(0.05)

0.01

(0.17)

(0.19)

Notes:

 

(1)

Acquisition and other costs are comprised costs and expenses in connection with the Company's acquisitions and business integration costs

(2)

Synergies realized relates to the impact of the full period of cost synergies related to the reduction of employees and professional services in relation to acquisitions

(3)

One-time costs related to IPO specific adjustments, acquisitions specific adjustments and transition costs related to the Wellbeats acquisition

(4)

"Adjusted Net Income (Loss)" has the meaning ascribed herein under "Cautionary Note Regarding Non-IFRS Measures and Key Performance Indicators."

(5)

"Adjusted earnings (loss) per share – basic" has the meaning ascribed herein under "Cautionary Note Regarding Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators"

(6)

"Adjusted earnings (loss) per share – diluted" has the meaning ascribed herein under "Cautionary Note Regarding Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators"

Key Performance Indicators

Annual Recurring Revenue

"Annual Recurring Revenue" or "ARR" is equal to the annualized value of contracted recurring revenue from all clients of our platform at the date being measured. Contracted recurring revenue is revenue generated from clients who are, as of the date being measured, party to contracts with LifeSpeak. Such revenue is annualized by: (i) in the case where a contract was in existence for the entire month, multiplying recognized revenue in the calendar month of the date measured by 12; and (ii) in the case where a contract was entered into mid-month, extrapolating recognized revenue at the date measured for the entire calendar month, and then multiplying by 12. Contract lengths typically range from one to three years and, based on our past experience, the vast majority of clients renew their contracts upon expiry. ARR is mainly comprised of revenue from enterprise and embedded solutions and includes revenue from small business and ancillary services (comprised of portals, kits and events purchased by our existing clients or distributed through our channel partners). ARR provides a consolidated measure by which we can monitor the longer-term trends in our business.

"Enterprise client ARR" is ARR at a particular date attributable to enterprise clients.

Net Dollar Retention Rate

"Net Dollar Retention Rate" for a period is defined by considering a cohort of clients at the beginning of the period, and dividing the ARR from enterprise and embedded solutions attributable to that cohort at the end of the period, by the ARR from enterprise and embedded solutions attributable to that cohort at the beginning of the period. Net Dollar Retention Rate provides a consolidated measure by which we can monitor the percentage of recurring ARR retained from existing clients.

Number of Clients

"Number of Clients" is defined as the number of clients at the end of any particular period as the number of enterprise clients and clients of our embedded solutions for which the term of services has not ended, or with which the Company is negotiating contract renewal and which meet a minimum revenue threshold.

Logo Retention Rate

"Logo Retention Rate" for a period is defined by considering a cohort of clients at the beginning of the period, and dividing the Number of Clients from that cohort at the end of the period, by the Number of Clients from that cohort at the beginning of the period. Logo Retention Rate provides a consolidated measure by which the Company can monitor the percentage of contracted clients retained every year.

About LifeSpeak Inc.

Celebrating 20 years of supporting employee wellbeing, LifeSpeak Inc. is the leading provider of mental, physical, and family wellbeing solutions for employers, health plans, and other organizations across the globe. With a suite of digital solutions, LifeSpeak enables organizations to deliver best-in-class content and human expertise at scale, catering to individuals throughout their wellbeing journeys. The LifeSpeak Inc. portfolio of solutions spans every pillar of wellbeing, including LifeSpeak Mental Health & Resilience, Wellbeats Wellness, Torchlight Parenting & Caregiving, ALAViDA Substance Use, and LIFT session Fitness. Insights from LifeSpeak Inc.'s digital and data-driven solutions empower organizations and individuals to take impactful action to strengthen wellbeing and maximize workplace performance. To learn more, follow LifeSpeak Inc. on LinkedIn (http://www.linkedin.com/company/lifespeak-inc), or visit www.LifeSpeak.com. Because wellbeing can't wait.

Forward-Looking Information

This press release may contain "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking information may relate to the Company's future business, financial outlook and anticipated events or results and may include information regarding the Company's financial position, business strategy, growth strategies, addressable markets, budgets, operations, financial results, taxes, and the Company's plans and objectives. In some cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "budget", "scheduled", "estimates", "outlook", "forecasts", "projection", "prospects", "strategy", "intends", "anticipates", "does not anticipate", "believes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might", "will", "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances contain forward-looking information. Particularly, information regarding the Company's expectations of future results, revenue growth, ARR, EBITDA, adjusted EBITDA margin, adjusted EBITDA, adjusted Net Income (Loss), adjusted Earnings (Loss), Number of Clients, Net Dollar Retention Rate, Logo Retention Rate, performance, synergies, achievements, prospects, industry trends, advancement of its strategy and acceleration of its growth, amortization, contribution of new clients to ARR, the amortization schedule and loan repayments, the among of senior indebtedness remaining, or opportunities, including for cross-selling, or the markets in which the Company operates is forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding possible future events or circumstances.

This forward-looking information and other forward-looking information are based on opinions, estimates and assumptions in light of the Company's experience and perception of historical trends, current conditions and expected future developments, as well as other factors that the Company currently believes are appropriate and reasonable in the circumstances. Despite a careful process to prepare and review the forward-looking information, there can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct. These opinions, estimates and assumptions include, but are not limited to, the following: the Company's ability to build its market share and enter new geographies; the total available market for its products; the Company's ability to retain key personnel; the Company's ability to maintain and expand geographic scope; the Company's ability to execute on its expansion plans; the Company's ability to continue investing in infrastructure to support its growth and brand recognition; the Company's ability to maintain its existing client base; the Company's ability to continue maintaining and enhancing its technological infrastructure and functionality of its platform; to the Company's ability to obtain financing on acceptable terms; the Company's ability to meet its amortization schedule in the future; decisions made by the Company's lenders; the Company's ability to effectively integrate its recent acquisitions; the Company's ability to generate sufficient cash to deleverage, the impact of competition; the changes and trends in the Company's industry or the global economy; and changes in laws, rules, regulations, and global standards.

The risks and uncertainties that may affect forward-looking statements include, among others: performance of the market sectors that the Company serves; general market performance including capital market conditions and availability and cost of credit; foreign currency and exchange risk; impact of factors such as increased pricing pressure and possible margin compression; the regulatory and tax environment; that expected cost and revenue synergies are not realized within the expected timeframe or at all; that revenue, ARR, EBITDA margin and cash flow expectations are not met for any number of reasons; political, labour or supplier disruptions; that our clients face recessionary pressures, and other risks detailed from time to time in the Company's filings with Canadian provincial securities regulators, including the risk factors which are described in greater detail under "Risk Factors" in the Company's annual information form for the fiscal year ended 2022 and the Company's annual information form which is to be filed on or before March 30, 2024. Although the Company has attempted to identify important risk factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other risk factors not currently known to the Company or that the Company currently believes are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information.

Accordingly, prospective investors should not place undue reliance on forward-looking information. The forward-looking information contained in this press release represents the Company's expectations as of the date of this press release (or as the date it is otherwise stated to be made) and is subject to change after such date. However, the Company disclaims any intention or obligation or undertaking to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required under applicable Canadian securities laws.

All of the forward-looking information contained in this press release is expressly qualified by the foregoing cautionary statements. Prospective investors should read this entire press release and consult their own professional advisors to ascertain and assess the income tax, legal, risk factors and other aspects of an investment in the Company.

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB